Placebo Controlled Trial of Bosentan in Scleroderma Patients
NCT00377455 is a phase 2 interventional trial sponsored by Georgetown University. As of 21 Nov 2026, it was terminated. It studies Bosentan monohydrate and Placebo in Pulmonary Hypertension and Systemic Scleroderma. The registry lists an enrollment of 5 participants at 2 sites in 1 country. The registry lists a start date of 30 Sept 2006 and a primary completion date of 30 Sept 2009.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00377455 |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Georgetown University |
| Enrollment | 5 |
| Registered sites | 2 |
| Countries | 1 |
| Conditions | Pulmonary Hypertension and Systemic Scleroderma |
| Drugs | Bosentan monohydrate and Placebo |
| Start | 30 Sept 2006 |
| Primary completion | 30 Sept 2009 |
| Study completion | 31 Mar 2010 |
| Last update posted | 24 May 2018 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Virginia D Steen, MD
Georgetown University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Connecticut
Farmington
- Georgetown University Medical Center
Washington D.C.
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00377455
Each answer restates registry values shown on this page.
What is NCT00377455?
NCT00377455 is a phase 2 interventional trial sponsored by Georgetown University. It studies Bosentan monohydrate and Placebo in Pulmonary Hypertension and Systemic Scleroderma.
Who leads NCT00377455?
The registry names Virginia D Steen, MD (principal investigator, Georgetown University) as the overall official.
Where does NCT00377455 run?
The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT00377455 study?
The registered drug and biological interventions are Bosentan monohydrate and Placebo.
When did NCT00377455 end?
The registry lists a primary completion date of 30 Sept 2009 and a study completion date of 31 Mar 2010. The sponsor last updated the record on 24 May 2018.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.